Oct 8 (Reuters) - Transcode Therapeutics Inc RNAZ.O:
TRANSCODE THERAPEUTICS (RNAZ) ANNOUNCES THE ACQUISITION OF POLYNOMA AND A $25 MILLION STRATEGIC FINANCING BY A SUBSIDIARY OF CK LIFE SCIENCES TO FORM A FIRST-IN-CLASS UNIQUE IMMUNO-ONCOLOGY AND METASTATIC PREVENTION ONCOLOGY COMPANY
TRANSCODE THERAPEUTICS INC - CONCURRENT EQUITY INVESTMENT OF $25 MILLION FROM CK LIFE SCIENCES INTO TRANSCODE
TRANSCODE THERAPEUTICS INC: PHILIPPE CALAIS APPOINTED AS TRANSCODE'S CHIEF EXECUTIVE OFFICER AND REMAINS CHAIRMAN
TRANSCODE THERAPEUTICS INC: TOM FITZGERALD STEPS DOWN AS INTERIM CHIEF EXECUTIVE OFFICER BUT REMAINS CHIEF FINANCIAL OFFICER